Health insurance benefit, another obstacle for Xeljanz to overcome

‘Xeljanz(generic name: tofacitinib),’ the world’s first oral rheumatoid arthritis treatment, has gotten over the wall of leading large hospitals in Korea.

However, due to the limitation in the health insurance benefit, even more patients are not able to take the advantage, which raises a voice to register the drug in the health insurance benefit.

Pfizer Pharmaceuticals Korea’s ‘Xeljanz’ is a ...